PRQR stock information

Sector:

Healthcare

Description:

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics N.V. website

Current Price

$1.89

RSI

64.69

Market Capitalization:

64.9M

Beta:

0.901

Volume:

325,800

Analyst Target Price:

$ 1.47

Economiic Fair Price:

Earnings DateNovember 02, 2022

Report DateJune 30, 2022

QuarterQ2

Forward Dividend N/A

Forward Dividend Rate N/A

Dividend N/A

Dividend Rate N/A

Payout Ratio N/A

Cash156.4M

Debt60.9M

EPS-0.96

Profit MarginN/A

Revenue Per Share TTM0.055

Return On Equity TTM-0.745

YoY Revenue Growth (TTM)

80.45 %

YoY Pre Tax Income Growth (TTM)

-15.15 %

YoY Free Cash Flow (TTM)

5.59 %

QoQ Revenue Growth

321.81 %

QoQ Pre Tax Income Growth

6.69 %

QoQ Free Cash Flow Growth

-50.28 %

2021 Revenue

$ 1.4M

2021 Free Cash Flow

$ -26.5M

44.78 %

2020 Free Cash Flow

$ -48M

-7.71 %

2019 Free Cash Flow

$ -44.6M

-54.66 %

2018 Free Cash Flow

$ -28.8M

17.87 %

2017 Free Cash Flow

$ -35.1M

4.59 %

2016 Free Cash Flow

$ -36.8M

2021 Pre Tax Income

$ -61.6M

ProQR Therapeutics N.V.(PRQR)